A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults

A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults

The purpose of this study is to demonstrate the efficacy of GSK Biologicals' influenza vaccine (Fluarix™) administered intramuscularly in adults.

Inclusion Criteria:

• A male or female age between 18 and 64 years at the time of the first vaccination.
• non-childbearing female

Exclusion Criteria:

• Use of non-registered products
• Pregnancy
• Hypersensitivity to a previous dose of influenza vaccine
• Acute disease at the time of enrolment/vaccination.
• History of allergy or reactions likely to be exacerbated by any component of the vaccine
• Administration of any other influenza vaccine for the season 2006-2007
• Chronic disorders of the pulmonary or cardiovascular system, including asthma.
• Administration of immune-modifying drugs
• Administration of immunoglobulins and/or any blood products
• History of requiring regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, asthma or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus)